Tumor Volume Kinetic Analyses Might Explain Excellent Prognoses in Young Patients with Papillary Thyroid Carcinoma.
Journal
Journal of thyroid research
ISSN: 2090-8067
Titre abrégé: J Thyroid Res
Pays: United States
ID NLM: 101536655
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
04
2020
revised:
18
06
2020
accepted:
23
06
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
1
8
2020
Statut:
epublish
Résumé
Young patients with papillary thyroid carcinoma (PTC) generally have excellent prognoses despite their often-advanced disease status. The reasons for this excellent prognosis are poorly understood. To investigate the natural history of PTC in young patients, we compared the observed tumor volume-doubling rate (TV-DR) with the hypothetical tumor volume-doubling rate (hTV-DR) before presentation in young PTC patients. DR is an inverse of the doubling time and indicates the number of doublings that occur in a unit of time. A negative value indicates the number of times the volume is reduced by half per unit time. We enrolled 20 patients with the following characteristics: age ≤19 years, diagnosed with PTC according to the cytology results between 2013 and 2018 and followed-up with periodical ultrasound examinations for ≥3 months before surgery for various reasons. Seventeen patients later underwent surgery confirming the diagnosis. We calculated TV-DRs using serial measurements of tumor diameters after presentation and hTV-DRs using tumor diameters and patients' age at presentation, assuming that a single cancer cell was present at the patient's birth and that the tumor grew at a constant rate. These values indicate the lowest growth rates necessary for a single cancer cell to achieve the full tumor size at presentation. Thirteen patients had positive TV-DRs (/year) ranging from 0.09 to 1.89, indicating tumor growth, and the remaining seven patients had negative values (-0.08 to -1.21), indicating regression. The median TV-DR was 0.29. The hTV-DRs (1.48-2.66, median 1.71) were significantly larger than the TV-DRs ( These data suggest that deceleration of tumor growth had already occurred at presentation in the majority of the cases. This might explain why disease-specific survival is excellent despite frequent findings of advanced disease in young patients with PTC.
Identifiants
pubmed: 32733666
doi: 10.1155/2020/4652767
pmc: PMC7383345
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4652767Informations de copyright
Copyright © 2020 Toshihiko Kasahara et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this article.
Références
Cancer. 1989 Jun 1;63(11):2207-10
pubmed: 2541886
Gastroenterology. 1985 Aug;89(2):259-66
pubmed: 2408960
J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63
pubmed: 11297567
JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1015-1020
pubmed: 28859191
In Vivo. 1998 Nov-Dec;12(6):571-8
pubmed: 9891219
Cancer. 2017 Aug 1;123(15):2955-2964
pubmed: 28369717
J Clin Endocrinol Metab. 2017 Mar 1;102(3):793-800
pubmed: 27809646
Endocr J. 2012;59(7):539-45
pubmed: 22472193
Endocr J. 2013;60(4):415-21
pubmed: 23182919
Am J Roentgenol Radium Ther Nucl Med. 1956 Nov;76(5):988-1000
pubmed: 13362715
PLoS One. 2015 Dec 10;10(12):e0144144
pubmed: 26657267
Cancer. 1993 Jun 1;71(11):3547-51
pubmed: 8490903
JAMA. 1998 Sep 16;280(11):975-80
pubmed: 9749479
Surgery. 2019 Jan;165(1):25-30
pubmed: 30413323
Ann Surg. 1984 Apr;199(4):461-6
pubmed: 6712322
Breast Cancer Res. 2008;10(3):R41
pubmed: 18466608
World J Surg. 2018 Feb;42(2):329-342
pubmed: 29030676
Thyroid. 2011 Jul;21(7):707-16
pubmed: 21649472
J Thyroid Res. 2018 May 16;2018:6470251
pubmed: 29862009